BMRK-05 ASSOCIATION BETWEEN HER2-LOW STATUS AND TIME TO DEVELOPMENT OF BRAIN METASTASES AMONG PATIENTS WITH BREAST CANCER: A RETROSPECTIVE COHORT STUDY
Bibliographic record
Abstract
Abstract BACKGROUND Brain metastases (BrM) develop in a high proportion of patients with breast cancer. We aimed to investigate the association between HER2 status (HER2-0, HER2-low, HER2+) and time to BrM development in patients treated for breast cancer BrM. METHODS We investigated a cohort of 188 women with metastatic breast cancer (MBC) treated for BrM at Sunnybrook Odette Cancer Centre from 2008-2018, for whom HER2 status was available in either the primary breast cancer (PBC) or metastatic site. We investigated: (1) association between HER2 status of the PBC (when available) and time from PBC to BrM diagnosis (PBC-TTBM), and (2) association between HER2 status of either PBC or metastatic site (the higher level of HER2 expression was utilized when >1 sample was available) and time from MBC to BrM diagnosis (MBC-TTBM). RESULTS Median age was 50 years and 54% of patients had >1 BrM. 40 patients had triple-negative breast cancer (TNBC), 77 had HER2+ disease, and 70 had HR+(hormone receptor+)/HER2- disease. Among 129 patients for whom PBC HER2 status was available, median PBC-TTBM was 44 months. HER2-low (n=29) status was associated with shorter PBC-TTBM compared to HER2-0 (n=60) and HER2+ (n=40) status (33 vs. 50 vs. 52 months, p=0.045). Among patients with HR+/HER2- disease, HER2-low status (n=21) was associated with shorter PBC-TTBM compared to HER2-0 status (n=29) (34 vs. 95 months, p<0.001). Among patients with TNBC, PBC-TTBM was similar among patients with HER2-low (n=8) and HER2-0 (n=31) status (24 vs. 27 months, p=0.79). In all patients, median MBC-TTBM was 21 months. MBC-TTBM was similar among patients with HER2-0 (n=58), HER2-low (n=53) and HER2+ (n=77) disease (15 vs.19 vs. 22 months, p=0.75); no differences were observed within the HR+/HER2- and TNBC subgroups. CONCLUSIONS HER2-low status is associated with shorter PBC-TTBM, particularly among patients with HR+/HER2- disease.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".